Evidence map›Paper›PMID 41145746›Full record

ArticlePharmaceutical research2025

Profiling Interactions Between Bicyclol and SLC/ABC Transporters: Advancing Clinical Safety and Efficacy in Combination Therapy.

Wanting Bai, Yang Li, Feng You, Xiaoyan Duan, Jiahuan Hu, Jinjin Wu, Tao Sun, Xing Wang, Pei Lan, Jinping Hu

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Wanting Bai *State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Key Laboratory of Non-Clinical Drug Metabolism and PK/PD Study, Department of Drug Metabolism, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, BeijingBeijing, 100050, China.
Yang Li *Beijing Union Pharmaceutical Factory Co., Ltd. , Beijing, 102600, China.
Feng You *Beijing Union Pharmaceutical Factory Co., Ltd. , Beijing, 102600, China.
Xiaoyan DuanState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Key Laboratory of Non-Clinical Drug Metabolism and PK/PD Study, Department of Drug Metabolism, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, BeijingBeijing, 100050, China.
Jiahuan HuState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Key Laboratory of Non-Clinical Drug Metabolism and PK/PD Study, Department of Drug Metabolism, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, BeijingBeijing, 100050, China.
Jinjin WuState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Key Laboratory of Non-Clinical Drug Metabolism and PK/PD Study, Department of Drug Metabolism, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, BeijingBeijing, 100050, China.
Tao SunBeijing Union Pharmaceutical Factory Co., Ltd. , Beijing, 102600, China.
Xing WangBeijing Union Pharmaceutical Factory Co., Ltd. , Beijing, 102600, China.
Pei LanBeijing Union Pharmaceutical Factory Co., Ltd. , Beijing, 102600, China. acetone@263.net.
Jinping HuState Key Laboratory of Bioactive Substance and Function of Natural Medicines, Key Laboratory of Non-Clinical Drug Metabolism and PK/PD Study, Department of Drug Metabolism, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, BeijingBeijing, 100050, China. hujp@imm.ac.cn.

Funding

Chinese Academy of Medical Sciences Initiative for Innovative Medicine No. 2023-I2M-2-006
6 · The paper itself

Abstract

objectiveBicyclol, a hepatoprotective agent, is often used in combination with other drugs for liver diseases, including drug-induced liver injury (DILI), raising concerns about potential drug-drug interactions (DDIs). This study investigates the interaction between bicyclol and key transporters (OATP1B1, OATP1B3, OAT1, OAT3, OCT2, MATE1, MATE2-K, P-gp, BCRP, BSEP) to predict transporter-related DDI risks.

methodsTransporter interaction studies were conducted using cell lines or membrane vesicles overexpressing human uptake and efflux transporters. The substrate and inhibitory potential of bicyclol were systematically evaluated through transport and inhibition assays. The static model and criteria were applied to assess the risk of transporter-related DDIs in vivo.

resultsBicyclol was not a substrate of above-mentioned transporters. Regarding inhibition, it was not an inhibitor of OATP1B1, OATP1B3, OAT1, OAT3, MATE1, MATE2-K, or BSEP (IC

conclusionsHere, we systematically elucidated the substrate and inhibition potential of bicyclol on major human drug transporters for the first time, which may provide the basis for rational co-administration of bicyclol, potentially broadening its clinical application.

Indexed as

ATP-Binding Cassette TransportersBiphenyl CompoundsAnimalsBiological TransportDrug InteractionsDrug Therapy, CombinationHEK293 CellsHumansATP-Binding Cassette TransportersbicyclolBiphenyl Compoundsbicycloldrug-drug interactionsdrug-induced liver injurydrug transporterspharmacokinetics

Identifiers

PMID41145746

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.